People · Operator
Named in public records as an officer, director or promoter · active 2022–2022 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vitara Biomedical, Inc. | — | Biotechnology | Series B | $70.0M | $63.3M | 2022 |
Rosaleen Oskanian at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Rosaleen Oskanian on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Kelly | 1 | 7 |
| Ian Ratcliffe | 1 | 6 |
| Manish Kothari | 1 | 6 |
| Bernard Lyons | 1 | 3 |
| Ted Fjallman | 1 | 2 |
| Thomas Todorow | 1 | 2 |
| Diem Nguyen | 1 | 1 |
| James McGlone | 1 | 1 |
| Monash Kothari | 1 | 1 |
| Arthur Dantchik | 1 | 1 |
| Jeffrey Kahn | 1 | 1 |
| Nelson Hill | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.